Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nathan Singh

Showing results (21-30 of 51) with videos related to

Pageof 6
Sort By:
Annual Review of Medicine|November 27, 2013
Chimeric antigen receptor therapy for cancerDavid M Barrett, Nathan Singh, David L Porter, et al.
Nano Letters|January 18, 2020
Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell EngineeringMargaret M Billingsley, Nathan Singh, Pranali Ravikumar, et al.
Environmental Science & Technology|February 3, 2007
Reduction of Cr(VI) under acidic conditions by the facultative Fe(lll)-reducing bacterium Acidiphilium cryptumDavid E Cummings, Scott Fendorf, Nathan Singh, et al.
Journal of Orthopaedic Trauma|September 12, 2015
Reduction of Radiation Exposure From C-Arm Fluoroscopy During Orthopaedic Trauma Operations With Introduction of Real-Time DosimetryRita Baumgartner, Kiley Libuit, Dennis Ren, et al.
Cytotherapy|January 21, 2014
Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapyDavid M Barrett, Nathan Singh, Xiaojun Liu, et al.
Gynecologic Oncology|December 5, 2009
The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decadeLana E Kandalaft, Nathan Singh, John B Liao, et al.
Seminars in Cancer Biology|December 24, 2019
Mechanisms of resistance to CAR T cell therapiesNathan Singh, Elena Orlando, Jun Xu, et al.
Cancer Immunology Research|August 9, 2014
Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastomaNathan Singh, Xiaojun Liu, Jessica Hulitt, et al.
Cytotherapy|May 17, 2017
Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell functionNathan Singh, Ted J Hofmann, Zachary Gershenson, et al.
Cancer Immunology Research|July 17, 2024
Regulatory Considerations for Genome-Edited T-cell TherapiesJulie K Jadlowsky, Ju-Fang Chang, David H Spencer, et al.
Pageof 6

Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
Annual Review of Medicine|November 27, 2013
Chimeric antigen receptor therapy for cancerDavid M Barrett, Nathan Singh, David L Porter, et al.
Nano Letters|January 18, 2020
Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell EngineeringMargaret M Billingsley, Nathan Singh, Pranali Ravikumar, et al.
Environmental Science & Technology|February 3, 2007
Reduction of Cr(VI) under acidic conditions by the facultative Fe(lll)-reducing bacterium Acidiphilium cryptumDavid E Cummings, Scott Fendorf, Nathan Singh, et al.
Journal of Orthopaedic Trauma|September 12, 2015
Reduction of Radiation Exposure From C-Arm Fluoroscopy During Orthopaedic Trauma Operations With Introduction of Real-Time DosimetryRita Baumgartner, Kiley Libuit, Dennis Ren, et al.
Cytotherapy|January 21, 2014
Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapyDavid M Barrett, Nathan Singh, Xiaojun Liu, et al.
Gynecologic Oncology|December 5, 2009
The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decadeLana E Kandalaft, Nathan Singh, John B Liao, et al.
Seminars in Cancer Biology|December 24, 2019
Mechanisms of resistance to CAR T cell therapiesNathan Singh, Elena Orlando, Jun Xu, et al.
Cancer Immunology Research|August 9, 2014
Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastomaNathan Singh, Xiaojun Liu, Jessica Hulitt, et al.
Cytotherapy|May 17, 2017
Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell functionNathan Singh, Ted J Hofmann, Zachary Gershenson, et al.
Cancer Immunology Research|July 17, 2024
Regulatory Considerations for Genome-Edited T-cell TherapiesJulie K Jadlowsky, Ju-Fang Chang, David H Spencer, et al.
Pageof 6